Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.23504
Abstract: Key Points Question What are the factors associated with noncompletion of hepatocellular carcinoma (HCC) surveillance in patients with high risk? Findings In this cohort study including 629 patients with HCC, most patients did not undergo… read more here.
Keywords: hepatocellular carcinoma; carcinoma multicenter; surveillance hepatocellular; cohort ... See more keywords
Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.20963
Abstract: This cohort study assesses whether screening for hepatocellular carcinoma (HCC) is associated with improved survival among individuals with hepatitis C virus (HCV)–associated cirrhosis who achieved HCV cure in the Veteran’s Affairs health system. read more here.
Keywords: hepatocellular carcinoma; hepatitis virus; survival; screening hepatocellular ... See more keywords
Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.21019
Abstract: Key Points Question In patients with metabolic dysfunction–associated steatotic liver disease (MASLD), can those at high risk of developing hepatocellular carcinoma (HCC) be identified? Findings This prognostic study used electronic health record data from 1 811 461… read more here.
Keywords: steatotic liver; dysfunction associated; hepatocellular carcinoma; liver disease ... See more keywords
Locoregional Therapies for Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.47995
Abstract: Key Points Question Which locoregional therapy (LRT) or combination of LRT and systemic therapy is preferred for patients with nonmetastatic hepatocellular carcinoma? Findings In this meta-analysis of 40 randomized clinical trials (11 576 total patients), evidence… read more here.
Keywords: hepatocellular carcinoma; locoregional therapies; therapies hepatocellular;
Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.3888
Abstract: A 66-year-old woman with chronic hepatitis B infection and hepatocellular carcinoma presented with moderate radiating epigastric pain with nausea, anorexia, and water brash without emesis. What is your diagnosis? read more here.
Keywords: hepatocellular carcinoma; abdominal pain; subacute abdominal; pain patient ... See more keywords
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA surgery"
DOI: 10.1001/jamasurg.2022.2800
Abstract: Importance National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver transplant (LT). Recurrence of HCC after LT… read more here.
Keywords: hepatocellular carcinoma; year; survival; whose disease ... See more keywords
Management of Hepatocellular Carcinoma: A Review.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA surgery"
DOI: 10.1001/jamasurg.2022.7989
Abstract: Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer-related death worldwide. Recent advances in systemic and locoregional therapies have led to changes in many guidelines regarding systemic therapy,… read more here.
Keywords: hepatocellular carcinoma; review; disease; association study ... See more keywords
hnRNPU Functions as a Novel Therapeutic Target of c-Myc in the Progression of Hepatocellular Carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "FEBS letters"
DOI: 10.1002/1873-3468.13943
Abstract: Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality. Here, we found that hnRNPU is overexpressed in HCC tissues and is correlated with the poor prognosis of HCC patients. Besides, hnRNPU is… read more here.
Keywords: hepatocellular carcinoma; hnrnpu functions; hcc; target ... See more keywords
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12072
Abstract: Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are… read more here.
Keywords: hepatocellular carcinoma; palbociclib; hcc; pp5 ampk ... See more keywords
lncRNA‐PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12553
Abstract: Hepatocellular carcinoma (HCC) is a malignancy with one of the worst prognoses. Long noncoding RNA (lncRNA) are emerging as an important regulator of gene expression and function, leading to the development of cancer. The aim… read more here.
Keywords: hepatocellular carcinoma; hcc; pdpk2p; lncrna pdpk2p ... See more keywords
Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12593
Abstract: Hepatocellular carcinoma (HCC), with its ineffective therapeutic options and poor prognosis, represents a global threat. In the present study, we show that RAD52 motif 1 (RDM1), a key regulator of DNA double‐strand break repair and… read more here.
Keywords: hepatocellular carcinoma; loss rdm1; rdm1; p53 ... See more keywords